These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 21724670)

  • 1. Antipsychotic polypharmacy: are two ever better than one?
    Goff DC; Dixon L
    Am J Psychiatry; 2011 Jul; 168(7):667-9. PubMed ID: 21724670
    [No Abstract]   [Full Text] [Related]  

  • 2. Emerging guidelines for the use of antipsychotic polypharmacy.
    Stahl SM
    Rev Psiquiatr Salud Ment; 2013; 6(3):97-100. PubMed ID: 23485567
    [No Abstract]   [Full Text] [Related]  

  • 3. Antipsychotic polypharmacy: never say never, but never say always.
    Stahl SM
    Acta Psychiatr Scand; 2012 May; 125(5):349-51. PubMed ID: 22506490
    [No Abstract]   [Full Text] [Related]  

  • 4. Dopamine2 receptor occupancy and the action of clozapine: does it make a difference to add a neuroleptic?
    Meltzer HY
    Biol Psychiatry; 1999 Jul; 46(1):144-9. PubMed ID: 10394487
    [No Abstract]   [Full Text] [Related]  

  • 5. Atypical antipsychotics: mechanism of action.
    Seeman P
    Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antipsychotic Polypharmacy in Schizophrenia: Why Not?
    Guinart D; Correll CU
    J Clin Psychiatry; 2020 Apr; 81(3):. PubMed ID: 32369690
    [No Abstract]   [Full Text] [Related]  

  • 7. Monotherapy versus polypharmacy for hospitalized psychiatric patients.
    Strous RD; Lerner V
    Am J Psychiatry; 2005 Mar; 162(3):631-2; author reply 632-3. PubMed ID: 15741496
    [No Abstract]   [Full Text] [Related]  

  • 8. [Antipsychotic polypharmacy in high-utilising patients with schizophrenia].
    Schmidt-Kraepelin C; Puschner B; Loos S; Janssen B
    Psychiatr Prax; 2013 Oct; 40(7):380-4. PubMed ID: 23681790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indirect modulation of dopamine D2 receptors as potential pharmacotherapy for schizophrenia: III. Retinoids.
    Citver AS; Shields AM; Ciaccia LM; Schulingkamp RJ; Raffa RB
    J Clin Pharm Ther; 2002 Jun; 27(3):161-8. PubMed ID: 12081629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positive findings for negative symptoms of schizophrenia: no longer untreatable?
    Stahl SM
    Acta Psychiatr Scand; 2006 Nov; 114(5):301-2. PubMed ID: 17022789
    [No Abstract]   [Full Text] [Related]  

  • 11. Antipsychotic polypharmacy in schizophrenia: evolving evidence and rationale.
    Azorin JM; Simon N
    Expert Opin Drug Metab Toxicol; 2020 Dec; 16(12):1175-1186. PubMed ID: 32930009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antipsychotic drug combinations in the treatment of schizophrenia. A review of the literature].
    Gazdag G; Tolna J; Bitter I
    Neuropsychopharmacol Hung; 2012 Sep; 14(3):189-95. PubMed ID: 22987732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High plasma prolactin levels after long-term neuroleptic treatment.
    Zelaschi NM; Delucchi GA; Rodriguez JL
    Biol Psychiatry; 1996 May; 39(10):900-1. PubMed ID: 8860193
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical and social determinants of antipsychotic polypharmacy for Chinese patients with schizophrenia.
    Xiang YT; Weng YZ; Leung CM; Tang WK; Ungvari GS
    Pharmacopsychiatry; 2007 Mar; 40(2):47-52. PubMed ID: 17447172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopamine receptors and schizophrenia.
    Reynolds GP
    Biochem Soc Trans; 1996 Feb; 24(1):202-5. PubMed ID: 8674664
    [No Abstract]   [Full Text] [Related]  

  • 16. Measuring efficacy of polypharmacy in schizophrenic inpatients.
    Lindenmayer JP
    J Clin Psychiatry; 2004 Aug; 65(8):1148; author reply 1148. PubMed ID: 15323607
    [No Abstract]   [Full Text] [Related]  

  • 17. Antipsychotic polypharmacy is not associated with reduced dose of individual antipsychotics in schizophrenia.
    John AP; Dragovic M
    J Clin Psychopharmacol; 2015 Apr; 35(2):193-5. PubMed ID: 25679123
    [No Abstract]   [Full Text] [Related]  

  • 18. Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003.
    Morrato EH; Dodd S; Oderda G; Haxby DG; Allen R; Valuck RJ
    Clin Ther; 2007 Jan; 29(1):183-95. PubMed ID: 17379060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monotherapy versus polypharmacy for hospitalized psychiatric patients.
    Citrome L; Jaffe A; Levine J
    Am J Psychiatry; 2005 Mar; 162(3):631; author reply 632-3. PubMed ID: 15741497
    [No Abstract]   [Full Text] [Related]  

  • 20. An importance of dose in antipsychotic combination therapy for schizophrenia.
    Suzuki T
    J Clin Psychopharmacol; 2011 Jun; 31(3):399; author reply 399-400. PubMed ID: 21532376
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.